### APOE ε4 carriage associates with improved myocardial performance in older age

Constantin-Cristian Topriceanu <sup>1,2,3</sup>, Mit Shah.<sup>5</sup>, Matthew Webber<sup>1,2</sup>, Fiona Chan<sup>1,2</sup>, James C Moon <sup>2,3</sup>, Marcus Richards<sup>1</sup>, Nishi Chaturvedi<sup>1,2</sup>, Alun D. Hughes<sup>1,2</sup>, Jonathan Schott<sup>1,6</sup>, Declan P. O'Regan.<sup>5</sup>, Gabriella Captur <sup>1,2,3,7</sup>

### **Author Affiliations:**

- 1. UCL MRC Unit for Lifelong Health and Ageing, University College London, London, UK
- 2. UCL Institute of Cardiovascular Science, University College London, London, UK
- 3. Cardiac MRI Unit, Barts Heart Centre, West Smithfield, London, UK
- National Heart and Lung Institute, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, UK
- 5. MRC London Institute of Medical Sciences, Imperial College London, London, UK
- 6. Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
- 7. The Royal Free Hospital, Centre for Inherited Heart Muscle Conditions, Cardiology Department, Pond Street, Hampstead, London, UK

## **Corresponding author:**

### Gabriella Captur

Consultant Cardiologist in Inherited Heart Muscle Conditions, Senior Clinical Lecturer

Institute of Cardiovascular Science,

University College London, Gower Street, London WC1E 6BT, UK

E-mail: gabriella.captur@ucl.ac.uk, Phone No: +44 2074600595

## ABSTRACT

**Introduction:** Although *APOE* ε4 allele carriage confers a risk of coronary disease, its persistence in human populations might be explained by certain survival advantages (antagonistic pleiotropy).

**Hypothesis**: Combining data from three British cohorts–1946 National Survey of Health and Development (NSHD), Southall and Brent Revised (SABRE) and UK Biobank–we explored whether *APOE*  $\varepsilon$ 4 carriage associates with beneficial or unfavorable left ventricular (LV) structural and functional parameters by echocardiography and cardiovascular magnetic resonance (CMR) in older age.

**Methods**: Based on the presence of *APOE*  $\varepsilon$ 4, genotypes were divided into: *APOE*  $\varepsilon$ 4 ( $\varepsilon$ 2 $\varepsilon$ 4,  $\varepsilon$ 3 $\varepsilon$ 4,  $\varepsilon$ 4 $\varepsilon$ 4) and non-*APOE*  $\varepsilon$ 4 carriers. Echocardiographic data included: LV ejection fraction, E/e', systolic and diastolic posterior wall and interventricular septal thickness (LVPWT<sub>s/d</sub>, IVS<sub>s/d</sub>), LV mass and the ratio of the LV stroke volume to the LV myocardial volume called myocardial contraction fraction (MCF). CMR data additionally included longitudinal and radial peak diastolic strain rates (PDSR). Generalized linear models explored associations between *APOE*  $\varepsilon$ 4 genotypes as exposures and echocardiographic/CMR biomarkers as outcomes. As APOE genotype is a genetic instrumental variable (unconfounded), Model 1 was unadjusted; Model 2 was adjusted for factors associated with the outcome (age, sex, and socio-economic position) to yield more precise estimates; and subsequent models were individually adjusted for mediators (body mass index, cardiovascular disease [CVD], high cholesterol and hypertension) to explore mechanistic pathways.

**Results**: 35,568 participants were included. Compared to the non-*APOE*  $\varepsilon$ 4 group, *APOE*  $\varepsilon$ 4 carriers had similar cardiac echocardiographic phenotypes in terms of LV EF, E/e', LVPWT<sub>s/d</sub>, IVS<sub>s/d</sub> and LV mass but had a 4% higher MCF (95% confidence interval [CI]: 1–7%, *p*=0.016) which persisted in Model 2 (95% CI 1–7%, *p*=0.008) but was attenuated to 3% after adjustment for CVD, diabetes and hypertension (all 95% CI 0–6%; all *p*<0.070). This was replicated in UK Biobank using CMR data, where *APOE*  $\varepsilon$ 4 carriers had a 1% higher MCF (95% CI 0-1%, *p*=0.020) which was attenuated only after adjusting for BMI or diabetes.

**Conclusions:** APOE  $\varepsilon$ 4 carriage associates with improved myocardial performance in older age resulting in greater LV stroke volume generation per 1 mL of myocardium and better longitudinal strain rates compared to non APOE  $\varepsilon$ 4 carriers. This potentially favorable cardiac phenotype adds to the growing number of reported survival advantages attributed to APOE  $\varepsilon$ 4 carriage that might collectively explain its persistence in humans.

**Keywords:** apolipoprotein  $\varepsilon$ 4, cardiovascular disease, myocardial contraction fraction.

### INTRODUCTION

Apolipoprotein  $\varepsilon$  (APOE  $\varepsilon$ ) mediates the biding of low-density lipoprotein (LDL) to peripheral receptors. Given the existence of two single-nucleotide polymorphisms, namely rs429358 and rs7412, there are three APOE  $\varepsilon$  isoforms coded by the alleles  $\varepsilon$ 2,  $\varepsilon$ 3 and  $\varepsilon$ 4 giving rise to six genotypes namely  $\varepsilon$ 2 $\varepsilon$ 2,  $\varepsilon$ 2 $\varepsilon$ 3,  $\varepsilon$ 2 $\varepsilon$ 4,  $\varepsilon$ 3 $\varepsilon$ 3,  $\varepsilon$ 3 $\varepsilon$ 4 and  $\varepsilon$ 4 $\varepsilon$ 4 with the commonest being  $\varepsilon$ 3 $\varepsilon$ 3<sup>1</sup>.

*Apolipoprotein*  $\varepsilon$ 4 is regarded to be a major risk factor for developing Alzheimer's disease<sup>2</sup> even from young age, especially in females <sup>3</sup>. In addition, it may associate with decreased physical performance in older age<sup>4</sup> and decrease cognitive performance (e.g., verbal episodic memory) in healthy young adults<sup>5</sup>. Yet despite its adverse associations, this ancestral allele has persisted in human populations instead of being replaced by the more recently evolved alleles,  $\varepsilon$ 3 and  $\varepsilon$ 2<sup>6</sup> suggesting its carriage might be conferring some survival advantages. Indeed, *APOE*  $\varepsilon$ 4 carriers have been shown to have increased fertility<sup>7,8</sup>, resistance to infections<sup>7</sup>, decreased perinatal and infant mortality<sup>7</sup>, decreased chronic airway obstruction <sup>9</sup>, fewer arterial aneurysms<sup>9</sup> and peptic ulcers<sup>9</sup>, less liver disease and slight cognitive advantages<sup>7 10</sup>.

In terms of the cardiovascular system, carriage of  $\varepsilon$ 4 (rs429358-cytosine and rs7412-cytosine) has been associated with adverse clinical sequelae including ischaemic heart disease (IHD)<sup>11</sup>, hypertension<sup>12</sup>, diabetes<sup>13</sup> and high LDL<sup>14</sup>. Moreover, heart function was also suggested to be a mediator in the association between *ApoE*  $\varepsilon$ 4 and gray matter decline<sup>15</sup>. However, to date it remains unclear whether *APOE*  $\varepsilon$ 4 carriage independently associates with a better or worse longterm cardiac phenotype in terms of heart size and function. Using cohort data from the Medical Research Council (MRC) 1946 National Survey of Health and Development (NSHD), Southall And Brent Revised (SABRE) and United Kingdom (UK) Biobank, we explored this association.

### METHODS

## **Study population**

The MRC NSHD is the world's longest-running birth cohort with continuous follow-up. In 1946 in Britain, 5,362 individuals (2547 males and 2815 females) born in the same week in March were enrolled. Participants were invited for periodic follow-ups in which health and socio-economic assessments were performed which have been described elsewhere<sup>16</sup>.

The SABRE study is a tri-ethnic cohort of European, South Asian, and African Caribbean participants living in North and West London. Between 1988-1981, participants aged 40-69 years were randomly selected from 5-year age and sex stratified primary care lists (n=4063) and workplaces (n=795). Full details have been described elsewhere<sup>17</sup>.

The UK Biobank is a large prospective cohort study with more than half a million individuals recruited between 2006 and 2010 when study participants were aged 40-69 years old, and features demographic, genetic, health outcome and imaging data for participants. <sup>18</sup>. Details of subjects' comorbidities were obtained through self-reported diagnoses and International Classification of Disease (ICD-9 and ICD-10) codes from linked medical records This project was conducted using the UK Biobank (UKBB) resource under application numbers 40616 and 46696.

### Data availability

NSHD data is available from: <u>https://www.nshd.mrc.ac.uk/data</u>, SABRE data is available from <u>https://www.sabrestudy.org/</u>, and UK Biobank data is available from <u>https://www.ukbiobank.ac.uk/</u>.

### **Ethical approval**

The 2006-2010 NSHD data collection sweep included an in-depth cardiovascular assessment and was granted ethical approval from the Greater Manchester Local Research Ethics Committee and the Scotland Research Ethics Committee<sup>16</sup> and written informed consent was given by all study participants. Similarly, the SABRE study was granted ethics approval from Ealing, Hounslow and Spelthorne, Parkside, and University College London Research Ethics Committees with all participants giving written consent. Our project was approved by both the SABRE and NSHD committees. UK Biobank's ethical approval was from the Northwest Multi-centre Research Committee (MRCEC) in 2011, which was renewed in 2016 and then in 2021. All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

#### **Outcomes: Echocardiographic data**

In NSHD, when study members were 60-64 years (2006-2010), British-based NSHD participants who had not been lost to follow-up or withdrawn, were invited to attend a clinic-based assessment that included resting transthoracic echocardiography using General Electric (GE) Vivid I machines. The echocardiographic protocol included long and short axis (LAX and SAX), apical 5-, 4-, 3- and 2- chamber, aortic SAX views <sup>19</sup>. In SABRE, study members were invited between 2008 and 2012 to a clinic visit in which echocardiographic data was acquired using a Phillips iE33 ultrasound machine S5-1 phased array and a X3-1 matrix transducer and analyzed using Philips QLAB software 7,0<sup>17</sup> in line with the with the American Society of Echocardiography (ASE) guidelines<sup>20</sup>. In both cohorts, echocardiographic data provided left ventricular (LV) ejection

fraction (EF), E/e', systolic and diastolic LV posterior wall and interventricular septal thickness (LVPWTs/d, IVSs/d), LV mass (LVmass). Myocardial contraction fraction (MCF) was calculated as the ratio between stroke volume and myocardial volume. Although indexation to body surface area (BSA), is commonly done in clinical practice, BSA is a poor indexation metric as it creates a bias for overweight individuals<sup>21</sup>. Although indexation to allometric height is a better alternative<sup>21</sup>, indexation might lead to spurious associations, as the exposure might be associated with height/weight rather than with the outcome itself. Therefore, we used unindexed echocardiographic outcomes in all subsequent analyses.

### **Outcomes: Cardiovascular magnetic resonance data**

Participants in the UK Biobank were randomly invited for a CMR scan on a 1.5 T Siemens Aera scanner from 2014. Briefly, the CMR imaging protocol consisted of three long-axis views and a complete short axis stack of balanced steady state free precession cines<sup>22</sup>. Grey-scale short axis cine stacks were automatically segmented using a deep learning neural network that has optimised for UKBB scan images, with human expert level performance <sup>23</sup>. The short-axis segmentations underwent post-processing to compute end-systolic, end-diastolic and stroke volumes in both ventricles <sup>24</sup>. Left ventricular mass (LVM) was computed from left ventricular volume (assuming a density of 1.05 g/ml). Left ventricular wall thickness was computed as the perpendicular radial-line distance between endocardial and epicardial surfaces at end-diastole for each of the 17 myocardial segments as defined by the American Heart Association (AHA)<sup>25</sup>. MCF was derived as above. Thickness of the IVS was calculated as the mean wall thickness of segments 2, 3, 8, 9 and 14, while PWT was taken as the mean of segments 5,6, 11, 12, and 16. To compute longitudinal and radial peak diastolic strain rates, non-rigid image co-registration was performed

<sup>26</sup>. Unindexed CMR metrics were used in all subsequent analyses as discussed above.

### Exposures: *APOE* ε genotype

In NSHD, blood samples were collected at age 53 by a trained research nurse, and DNA was extracted.<sup>27</sup> Genetic analysis of stored samples took place in in 1999 and 2006-2010. In SABRE, blood samples were collected during baseline studies in 1988-1991 and during follow-up from 2007-2012<sup>17</sup>. Genotyping of rs439358 and rs7412 was conducted at the Exeter University for SABRE and by LGC, Huddleston, UK for NSHD<sup>28</sup>. . Genotyping of UK Biobank participants is detailed elsewhere <sup>29</sup>, however in brief, genotyping for 488,252 subjects was performed using the UK BiLEVE or UK Biobank Axiom arrays and imputation based on the HaplotypeReference Consortium and UK10K+1000 Genomes panels. Imputation V3 (in GRCh37 coordinates) was used for the current study. Genotypes in their released PLINK-format files were used on the DNANexus platform (https://www.dnanexus.com/). Based on the presence or absence of *APOE*  $\varepsilon$ 4, genotypes were categorically defined as: non-*APOE*  $\varepsilon$ 4 ( $\varepsilon$ 2 $\varepsilon$ 2,  $\varepsilon$ 2 $\varepsilon$ 3,  $\varepsilon$ 3 $\varepsilon$ 3), heterozygous-*APOE*  $\varepsilon$ 4 ( $\varepsilon$ 2 $\varepsilon$ 4 and  $\varepsilon$ 3 $\varepsilon$ 4) or homozygous-*APOE*  $\varepsilon$ 4 carriers.

### Covariates

Sex was recorded as male or female. The age, weight, and height at the time of the imaging were used to compute the body mass index (BMI) in all 3 cohorts. In NSHD, participants' socioeconomic position (SEP) was evaluated at the time of echocardiography according to UK Surveys Registrar General's social class, dichotomized as manual or non-manual. In UK Biobank,

we used the Townsend deprivation index scores derived from national data about ownership and unemployment aggregated by postcodes<sup>30</sup>. The presence of cardiovascular disease (CVD), diabetes or high cholesterol was recorded as 1=present or 0=absent.

## Statistics

All analyses were performed in R 4.0  $^{31}$ . For all analyses, a two-tailed *p*-value <0.05 was considered statistically significant.

Distribution of data were assessed on histograms and using Shapiro-Wilk test. Continuous variables are expressed as mean  $\pm 1$  standard deviation (SD) or median (interquartile range) as appropriate; categorical variables, as counts and percent.

In the main analysis, we compared non-*APOE*  $\varepsilon$ 4 carriers with *APOE*  $\varepsilon$ 4 carriers. Given the skewed distributions of echocardiographic and CMR data, generalized linear models with gamma distribution and log link were used to investigate the association of *APOE*  $\varepsilon$ 4 genotypes as the exposures to predict the continuous echocardiographic and CMR variables as the outcomes. As the longitudinal and radial PDSR also spanned negative values, generalized linear models with Gaussian distribution and identity link were used instead. Being a combination of gene variants, *APOE*  $\varepsilon$  genotype is expected to be an instrumental variable and therefore unconfounded. Thus, Model 1 was unadjusted. To obtain more precise regression estimates, Model 2 was adjusted for factors associated with the outcome, namely age, sex, and SEP. To explore the mechanistic pathway downstream of *APOE*  $\varepsilon$  genotype but upstream of the echocardiographic outcomes, subsequent models were adjusted for mediators as follows: Model 3 for BMI; Model 4 for the presence of CVD; Model 5 for diabetes; Model 6 for high cholesterol; and Model 7 for

hypertension (**Figure 1**). Model assumptions were verified with regression diagnostics and found to be satisfied.

For all the models, regression estimates were obtained separately for NSHD, SABRE and UK Biobank (i.e., cohort specific analyses). Since both NSHD and SABRE participants had echocardiography, random-effects meta-analyses were performed across these 2 cohorts. Heterogeneity was evaluated using the Cochran Q test and Higgins I<sup>2</sup> statistic. Since UK Biobank had CMR data, it was not included in the meta-analysis.

To explore dose responses, *APOE*  $\varepsilon$ 4 genotypes were recoded as an ordered category based on the number of  $\varepsilon$ 4 possessed. Thus, class 0 =  $\varepsilon$ 2 $\varepsilon$ 2,  $\varepsilon$ 2 $\varepsilon$ 3,  $\varepsilon$ 2 $\varepsilon$ 3; class 1=  $\varepsilon$ 2 $\varepsilon$ 4 and  $\varepsilon$ 3  $\varepsilon$ 4; and class 2 =  $\varepsilon$ 4 $\varepsilon$ 4. Given the existence of 3 classes, generalized linear models with gamma distribution (or Gaussian distribution for longitudinal and radial PDSR) and orthogonal polynomial contrasts with 2 equally spaced levels (i.e., linear and quadratic) were employed to look for a dose response by  $\varepsilon$ 4 variants.

As a sensitivity analyses, *APOE*  $\varepsilon$ 4 carriers were split into heterozygous-*APOE*  $\varepsilon$ 4 ( $\varepsilon$ 2 $\varepsilon$ 4 and  $\varepsilon$ 3 $\varepsilon$ 4) and homozygous-*APOE*  $\varepsilon$ 4 ( $\varepsilon$ 4 $\varepsilon$ 4), and all the analyses were replicated as above.

### RESULTS

## **Participant characteristics**

Participants with available *APOE*  $\varepsilon$ 4 genotype and at least one cardiac imaging metric were included yielding a total of 35568 participants (n=1467 from NSHD, n=1187 from SABRE and n=32972 from UK Biobank). Their characteristics are shown in **Table 1**. In total, there were 816 (2.29%) homozygous-*APOE*  $\varepsilon$ 4, and 9103 (25.59%) heterozygous-*APOE*  $\varepsilon$ 4 individuals with a good agreement between NSHD, SABRE and UK Biobank. SABRE participants were more likely

to be males (76.75%), have a higher BMI (median 27 years) or suffer from hypertension (58.98%) compared to NSHD and UK Biobank. On the other hand, UK Biobank participants were least likely to suffer from CVD (6.53%), diabetes (18.64%) or hypertension (27.62%).

#### Associations between APOE $\varepsilon 4$ genotypes and echocardiographic data

In NSHD, when compared to the non-*APOE*  $\varepsilon$ 4 group, *APOE*  $\varepsilon$ 4 carriers had a 6% higher MCF (95% confidence interval [CI] 0-12%, *p*=0.050) which persisted after adjusting for sex and SEP (95% CI 0-12%, *p*=0.038) and diabetes (95% CI 0-12%, *p*=0.056), was attenuated to 5% after adjusting for BMI (95% CI 0-11%, *p*=0.064), CVD (95% CI 0-12%, *p*=0.112) and hypertension (95% CI 1-11%, *p*=0.081), and was increased to 8% after adjusting for high cholesterol (95% CI 1-14%, *p*=0.020, **Supplementary Table S1**). Similarly, *APOE*  $\varepsilon$ 4 carriers had a 5% higher LVmass *p*=0.057 which was increased to 6% after adjusting for CVD (*p*=0.040) and hypertension (*p*=0.040), and to 7% after adjusting for diabetes *p*=0.024. No significant associations were found in SABRE (**Supplementary Table S2**).

In the meta-analyses, compared to the non-*APOE*  $\varepsilon$ 4 group, *APOE*  $\varepsilon$ 4 carriers had similar cardiac phenotypes in terms of EF, E/e', LVPWT<sub>s/d</sub>, IVS<sub>s/d</sub> and LVmass but had a 4% higher MCF (95% CI 1–7%, *p*=0.016) which persisted after adjustment for sex and SEP (95% CI 1–7%, *p*=0.008) and was attenuated to 3% after adjustment for CVD, diabetes and hypertension (all 95% CI 0–6%, all *p*<0.070, **Table 2, Figure 1**). However, no significant dose response of *APOE*  $\varepsilon$ 4 carriage was found in the association of *APOE*  $\varepsilon$ 4 genotype with MCF (**Table 4, Supplementary Table S3**). In the sensitivity analysis, only heterozygous-*APOE*  $\varepsilon$ 4 carriers had a 4% higher MCF (95% CI 1-7%, *p*=0.016) which persisted after adjusting for sex and SEP (95% CI 1-7%, *p*=0.013), and BMI (95% CI 1-7%, *p*=0.018) but was attenuated to 3% after adjusting for CVD (95% CI 0-6%,

*p*=0.043, diabetes (95% 0-7%, *p*=0.060), and hypertension (95% CI 0-6%, *p*=0.028, **Table 5**, **Supplementary Table S4**).

### Associations between APOE *ɛ*4 genotypes and CMR data

In UK Biobank, when compared to the non-*APOE*  $\varepsilon$ 4 group, *APOE*  $\varepsilon$ 4 carriers had a 1% higher MCF 95% (CI 0-1%, p=0.020) which persisted after adjusting for age, sex and SEP (Model 2, p=0.080), CVD (Model 4, p=0.006), high cholesterol (Model 5, p=0.0001) and hypertension (Model 7, p=0.034) but was attenuated to 0% (95% CI 0-1%) after adjusting for BMI (Model 3, p=0.079) or diabetes (p=0.058, **Table 3, Figure 1**). There was a dose-response relationship especially when adjusting for CVD in Model 4 (p=0.036) and high cholesterol in Model 6 (p=0.006, **Table 4**). However, although heterozygous-*APOE*  $\varepsilon$ 4 carriers had a higher MCF, the association was not significant for homozygous-*APOE*  $\varepsilon$ 4 carriers (**Table 5**).

In addition, *APOE*  $\varepsilon$ 4 carriers had a 2% higher longitudinal PDSR (95% CI 0-3%, *p*=0.045), which persisted after adjusting for CVD and diabetes, but was attenuated to 0% in Model 2 and to 1% after adjusting for diabetes (Model 5). Conversely, they had a 5% lower radial PDSR (95% CI 0.90-1.00, *p*=0.05) which behaved similar to longitudinal PDSR on adjustment (**Table 3**).

### DISCUSSION

Data from >35,000 British older adults show that *APOE*  $\varepsilon$ 4 carriage associates with slightly advantageous myocardial performance manifesting as higher MCF and longitudinal strain rates, but slightly lower radial strain rates. A graphical abstract of this work is presented in **Figure 2**. *APOE*  $\varepsilon$ 4 might be another example of antagonistic pleiotropy<sup>6</sup> as  $\varepsilon$ 4 carriage appears to be both beneficial (e.g., fertility and resistance to infections<sup>7</sup>) and detrimental (e.g., Alzheimer's disease)

to human health. The occurrence of the latter further down the fertility timeline in older age might explain the allele's persistence in spite of natural selection.

In terms of cardiovascular health, APOE ɛ4 carriage was previously associated with CVD (IHD<sup>14</sup> and myocardial infarction<sup>32</sup>) and CVD risk factors (such as hypertension<sup>12</sup> and diabetes<sup>13</sup>). Although the exact mechanism is yet to be elucidated, it is postulated that APOE  $\varepsilon$ 4 might contribute to the development of metabolic syndrome<sup>33</sup>. APOE  $\varepsilon$ 4 differs from APOE  $\varepsilon$ 3 at amino acid position 112 where arginine (positively charged side chain) is present instead of cysteine (nonpolar side chain). Given its ability to bind to peripheral and hepatic lipoprotein receptors, it is plausible for the APOE  $\varepsilon$  isoforms to have different binding affinities explaining the link with dyslipidemia<sup>14</sup>. However, emerging evidence points to more a complex mechanism as APOE  $\varepsilon$  can also alter the levels of APOB<sup>34</sup> which is itself also associated with CVD<sup>35</sup>. In addition, APOE  $\varepsilon$  is mainly produced by the liver, but can also be synthesized in and regulate the activity of adipocytes<sup>36</sup> which might explain the relationship between APOE  $\varepsilon 4$  and insulin resistance <sup>33,37</sup>. Here we show that APOE  $\varepsilon 4$  carriage appears to associate with a higher MCF. The MCF is a volumetric index of LV myocardial shortening which captures maladaptive myocardial hypertrophy otherwise missed by conventional biomarkers such as EF, mass, and wall thickness, as it considers the relationship between LVmass and  $SV^{38}$ . It has been previously associated with CV morbidity and mortality independent of conventional risk factors<sup>39</sup>. In addition, it is regarded as a highly-sensitive metric of systolic function, and low values have been linked to negative outcomes even in the presence of apparently normal LV EF<sup>40</sup> indicating its strength as a subclinical disease marker. A higher MCF in the context of APOE ɛ4 carriage might mean a slightly advantageous cardiac phenotype in terms of heart function. Dissociable effects of APOE ɛ4 carriage have been previously reported in the context of better attention despite the higher risk of

Alzheimer's disease<sup>10</sup>. Although the literature is sparse, *APOE*  $\varepsilon$ 4 carriage has been previously linked to higher levels of androgens<sup>41</sup> or dysregulated glucose and ketone metabolism<sup>7</sup> which could putatively increase myocardial contractility leading to a higher stroke volume per unit of LV mass which is being captured by the MCF<sup>42</sup>. We go on to show that there is likely to be a dose response relationship based on the number of  $\varepsilon$ 4 alleles carried by an individual, as per the polynomial contrasts analyses (in the sensitivity analysis the association of homozygous *APOE*  $\varepsilon$ 4 with MCF likely did not persist as only 2.29% of individuals (816) were homozygous for *APOE*  $\varepsilon$ 4). Another explanation is that healthier *APOE*  $\varepsilon$ 4 carriers may have been more likely to survive and/or to participate in the studies resulting in selection bias. This would fit with the known effects of *APOE*  $\varepsilon$ 4 carriage on IHD, HT, lipids, and cognitive function. Previous studies have described cognitive advantages in heterozygotes that were not replicated in the homozygotes<sup>43</sup> mirroring our data.

Indeed, *APOE*  $\varepsilon$ 4 carriage was associated with a greater longitudinal but lower radial strain suggesting that different myocardial contraction dynamics might be contributing to the observed association with MCF. The observed trend linking *APOE*  $\varepsilon$ 4 carriage with slightly better echocardiographic LV filling pressures (lower E/e' may suggest less ventricular stiffness in some but not all cases<sup>44</sup>), albeit attenuated in multivariable models, lends plausibility to this theory. The CMR analyses indicated a slight association between *APOE*  $\varepsilon$ 4 carriage and thinner ventricular walls, and similarly the echocardiographic analyses found no association between *APOE*  $\varepsilon$ 4 carriage and LV hypertrophy biomarkers (LVPWT<sub>s/d</sub>, IVS<sub>s/d</sub>, LVmass). These data collectively suggest that the observed MCF enhancement is not mediated by pathological ventricular thickening but through improved myocardial energetics and contractility, with calcium potentially implicated<sup>41,42</sup>.

The main strength of our study is that we were able to replicate the findings in three independent cohorts encompassing >35000 individuals, across imaging modalities (echocardiography and CMR). In addition, as the MRC NSHD is a birth cohort, the participants were implicitity agematched across all the analyses, exposed to similar epoch-related risk factors and had access to similar treatment facilities across the decades. Since both SABRE and NSHD were longitudinal cohorts in which timing of genotyping and echocardiography were not necessarily contemporaneous, selective follow-up may have potentially excluded homozygous or heterozygous individuals who already passed away with the worst cardiac phenotypes.

#### CONCLUSION

APOE  $\varepsilon$ 4 carriage associates with improved myocardial performance in older age resulting in greater LV stroke volume generation per 1 mL of myocardium and better longitudinal strain rates compared to non APOE  $\varepsilon$ 4 carriers. This potentially favorable cardiac phenotype adds to the growing number of reported survival advantages attributed to APOE  $\varepsilon$ 4 carriage that might collectively explain its persistence in humans.

#### DECLARATIONS

#### **CONTRIBUTORS' STATEMENT**

G Captur and C Topriceanu conceptualized the study design and implementation, analyzed the data, interpreted the results, and wrote the manuscript. M.Shah, M Webber, F Chan, JC Moon, AD Hughes, N Chaturvedi, J Schott, M Richards, and DP O'Regan were involved in data acquisition and critically reviewed and revised the manuscript. All authors were involved in critically

reviewing and revising the manuscript, approved the final version as submitted and agree to be accountable for all aspects of the work.

## FUNDING

This study was funded by the UK Medical Research Council (program codes MC\_UU\_12019/1; MC\_UU\_12019/4; MC\_UU\_12019/5). G.C. is supported by British Heart Foundation (MyoFit46 Special Programme Grant SP/20/2/34841), the Barts Charity HeartOME1000 project grant (MGU0427 / G-001411) and by the NIHR UCL Hospitals Biomedical Research Centre. J.C.M. is directly and indirectly supported by the UCL Hospitals NIHR BRC and Biomedical Research Unit at Barts Hospital respectively. AH receives support from the British Heart Foundation, the Economic and Social Research Council (ESRC), the Horizon 2020 Framework Programme of the European Union, the National Institute on Aging, the National Institute for Health Research Council and works in a unit that receives support from the UK Medical Research Council. DP O'Regan is supported by the Medical Research Council (MC\_UP\_1605/13); National Institute for Health Research (NIHR) Imperial College Biomedical Research Centre; and the British Heart Foundation (RG/19/6/34387, RE/18/4/34215).

#### **ROLE OF THE FUNDING SOURCE**

None of the funders was involved in the study design, the collection, the analysis, the interpretation of the data, and in the decision to submit the article for publication.

For the purpose of open access, the authors have applied a creative commons attribution (CC

BY) license to any author accepted manuscript version arising.

# CONFLICT OF INTEREST DISCLOSURES

The views expressed in this article are those of the authors who declare that they have no conflict

of interest.

# **REFERENCES:**

- 1 Mahley, R. W. Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology. *Science (American Association for the Advancement of Science)* **240**, 622-630 (1988). <u>https://doi.org:10.1126/science.3283935</u>
- Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C. & Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. *Nature reviews*. *Neurology* 15, 501-518 (2019). <u>https://doi.org:10.1038/s41582-019-0228-7</u>
- 3 Neu, S. C. *et al.* Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. *JAMA neurology* **74**, 1178-1189 (2017). <u>https://doi.org:10.1001/jamaneurol.2017.2188</u>
- 4 Skoog, I. *et al.* Association between APOE Genotype and Change in Physical Function in a Population-Based Swedish Cohort of Older Individuals Followed Over Four Years. (2016).
- Nao, J. *et al.* Adverse effects of the apolipoprotein E ε4 allele on episodic memory, task switching and gray matter volume in healthy young adults. *Frontiers in human neuroscience* **11**, 346-346 (2017). https://doi.org:10.3389/fnhum.2017.00346
- 6 Tuminello, E. R. & Han, S. D. The Apolipoprotein E Antagonistic Pleiotropy Hypothesis: Review and Recommendations. *International journal of alzheimer's disease* **2011**, 726197-726112 (2011). <u>https://doi.org:10.4061/2011/726197</u>
- 7 Smith, C. J., Ashford, J. W. & Perfetti, T. A. Putative Survival Advantages in Young Apolipoprotein ε4 Carriers are Associated with Increased Neural Stress. *Journal of Alzheimer's disease* 68, 885-923 (2019). <u>https://doi.org:10.3233/JAD-181089</u>
- 8 Jasienska, G. *et al.* Apolipoprotein E (ApoE) polymorphism is related to differences in potential fertility in women: A case of antagonistic pleiotropy? *Proceedings of the Royal Society. B, Biological sciences* 282, 20142395-20142395 (2015). <u>https://doi.org:10.1098/rspb.2014.2395</u>
- 9 Lumsden, A. L., Mulugeta, A., Zhou, A. & Hyppönen, E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. *EBioMedicine* **59**, 102954-102954 (2020). https://doi.org:10.1016/j.ebiom.2020.102954
- Wolk, D. A. & Dickerson, B. C. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional—executive network function in Alzheimer's disease. *Proceedings of the National Academy of Sciences PNAS* **107**, 10256-10261 (2010). <u>https://doi.org:10.1073/pnas.1001412107</u>
- 11 Zhao, Q. R., Lei, Y. Y., Li, J., Jiang, N. & Shi, J. P. Association between apolipoprotein E polymorphisms and premature coronary artery disease: a meta-

analysis. CLIN CHEM LAB MED **55**, 284-298 (2017). https://doi.org:10.1515/cclm-2016-0145

- 12 Shi, J. *et al.* Association between ApoE polymorphism and hypertension: A metaanalysis of 28 studies including 5898 cases and 7518 controls. *GENE* **675**, 197-207 (2018). <u>https://doi.org:10.1016/j.gene.2018.06.097</u>
- 13 Chen, D. W., Shi, J. K., Li, Y., Yang, Y. & Ren, S. P. Association between ApoE Polymorphism and Type 2 Diabetes: A Meta-Analysis of 59 Studies. *BIOMED ENVIRON SCI* **32**, 823-838 (2019). <u>https://doi.org:10.3967/bes2019.104</u>
- 14 Khan, T. A. *et al.* Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: Systematic review and meta-analysis of 14 015 stroke cases and pooled analysis of primary biomarker data from up to 60 883 individuals. *INT J EPIDEMIOL* **42**, 475-492 (2013). <u>https://doi.org:10.1093/ije/dyt034</u>
- 15 Mueller, K. *et al.* Brain Damage With Heart Failure: Cardiac Biomarker Alterations and Gray Matter Decline. *Circulation research* **126**, 750-764 (2020). <u>https://doi.org:10.1161/CIRCRESAHA.119.315813</u>
- 16 Kuh, D. *et al.* Cohort profile: updating the cohort profile for the MRC National Survey of Health and Development: a new clinic-based data collection for ageing research. *Int J Epidemiol , 40 (1) e1-e9. (2011)* (2011).
- 17 Tillin, T., Forouhi, N. G., McKeigue, P. M. & Chaturvedi, N. Southall And Brent REvisited: Cohort profile of SABRE, a UK population-based comparison of cardiovascular disease and diabetes in people of European, Indian Asian and African Caribbean origins. *International Journal of Epidemiology* **41**, 33-42 (2012). <u>https://doi.org:10.1093/ije/dyq175</u>
- 18 Sudlow, C. et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLoS medicine 12, e1001779-e1001779 (2015). https://doi.org:10.1371/journal.pmed.1001779
- 19 Kuh, D. *et al.* Cohort profile: updating the cohort profile for the MRC National Survey of Health and Development: a new clinic-based data collection for ageing research. *Int J Epidemiol , 40 (1) e1-e9. (2011)* (2011).
- 20 Al Saikhan, L. *et al.* Relationship Between Image Quality and Bias in 3D Echocardiographic Measures: Data From the SABRE (Southall and Brent Revisited) Study. *Journal of the American Heart Association* **11**, e019183e019183 (2022). <u>https://doi.org:10.1161/JAHA.120.019183</u>
- Chirinos, J. A. *et al.* Left Ventricular Mass: Allometric Scaling, Normative Values, Effect of Obesity, and Prognostic Performance. *Hypertension (Dallas, Tex. 1979)* 56, 91-98 (2010). <u>https://doi.org:10.1161/HYPERTENSIONAHA.110.150250</u>
- 22 Petersen, S. E. *et al.* UK Biobank's cardiovascular magnetic resonance protocol. Journal of cardiovascular magnetic resonance **18**, 8-8 (2016). <u>https://doi.org:10.1186/s12968-016-0227-4</u>
- Bai, W. *et al.* Automated cardiovascular magnetic resonance image analysis with fully convolutional networks. *Journal of cardiovascular magnetic resonance* 20, 65-65 (2018). <u>https://doi.org:10.1186/s12968-018-0471-x</u>
- 24 Schulz-Menger, J. *et al.* Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized

Post-Processing. *Journal of cardiovascular magnetic resonance* **22**, 19-19 (2020). <u>https://doi.org:10.1186/s12968-020-00610-6</u>

- 25 Cerqueira, M. D. *et al.* Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart - A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation (New York, N.Y.)* **105**, 539-542 (2002). https://doi.org:10.1161/hc0402.102975
- 26 Thanaj, M. *et al.* Genetic and environmental determinants of diastolic heart function. (2022).
- 27 Rousseau, K. *et al.* MUC7 haplotype analysis: Results from a longitudinal birth cohort support protective effect of the MUC7 5 allele on respiratory function. *Annals of human genetics* **70**, 417-427 (2006). <u>https://doi.org:10.1111/j.1469-1809.2006.00250.x</u>
- 28 Rawle, M. *et al.* Apolipoprotein-E (ApoE) ε4 and cognitive decline over the adult life course. (2018).
- 29 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature (London)* **562**, 203-209 (2018). <u>https://doi.org:10.1038/s41586-018-0579-z</u>
- 30 Townsend, P., Beattie, A. & Phillimore, P. Health and deprivation : inequality and the north / Peter Townsend, Peter Phillimore and Alastair Beattie. (Routledge, 1989).
- 31 71-117 (2014).
- 32 Xu, H. *et al.* Meta-analysis of apolipoprotein e gene polymorphism and susceptibility of myocardial infarction. *PLOS ONE* **9**, e104608-e104608 (2014). <u>https://doi.org:10.1371/journal.pone.0104608</u>
- 33 Torres-Perez, E., Ledesma, M., Garcia-Sobreviela, M. P., Leon-Latre, M. & Arbones-Mainar, J. M. Apolipoprotein E4 association with metabolic syndrome depends on body fatness. *ATHEROSCLEROSIS* **245**, 35-42 (2015). <u>https://doi.org:10.1016/j.atherosclerosis.2015.11.029</u>
- Griffin, B. A. *et al.* APOE4 Genotype Exerts Greater Benefit in Lowering Plasma Cholesterol and Apolipoprotein B than Wild Type (E3/E3), after Replacement of Dietary Saturated Fats with Low Glycaemic Index Carbohydrates. *NUTRIENTS* 10, 1524 (2018). <u>https://doi.org:10.3390/nu10101524</u>
- 35 Richardson, T. G. *et al.* Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. *PLoS medicine* **17**, e1003062e1003062 (2020). <u>https://doi.org:10.1371/JOURNAL.PMED.1003062</u>
- 36 Tejedor, M. T., Garcia-Sobreviela, M. P., Ledesma, M. & Arbones-Mainar, J. M. The apolipoprotein e polymorphism rs7412 associates with body fatness independently of plasma lipids in middle aged men. *PLOS ONE* 9, e108605e108605 (2014). <u>https://doi.org:10.1371/journal.pone.0108605</u>
- 37 Arbones-Mainar, J. M., Johnson, L. A., Altenburg, M. K. & Maeda, N. Differential modulation of diet-induced obesity and adipocyte functionality by human apolipoprotein E3 and E4 in mice. *INT J OBESITY* **32**, 1595-1605 (2008). <u>https://doi.org:10.1038/ijo.2008.143</u>

- 38 King, D. L., El-Khoury Coffin, L. & Maurer, M. S. Myocardial contraction fraction: a volumetric index of myocardial shortening by freehand three-dimensional echocardiography. *Journal of the American College of Cardiology* **40**, 325-329 (2002). <u>https://doi.org:10.1016/s0735-1097(02)01944-7</u>
- 39 Chuang, M. L. M. D. *et al.* Usefulness of the Left Ventricular Myocardial Contraction Fraction in Healthy Men and Women to Predict Cardiovascular Morbidity and Mortality. *The American journal of cardiology* **109**, 1454-1458 (2012). <u>https://doi.org:10.1016/j.amjcard.2012.01.357</u>
- 40 Rubin, J., Steidley, D. E., Carlsson, M., Ong, M.-L. & Maurer, M. S. Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis. *Journal of Cardiac Failure* **24**, 504-511 (2018). <u>https://doi.org:10.1016/j.cardfail.2018.07.001</u>
- 41 Žofková, I., Zajíčková, K., Hill, M. & Hořínek, A. Apolipoprotein E gene determines serum testosterone and dehydroepiandrosterone levels in postmenopausal women. *European journal of endocrinology* **147**, 503-506 (2002). <u>https://doi.org:10.1530/eje.0.1470503</u>
- 42 Ayaz, O. & Howlett, S. E. Testosterone modulates cardiac contraction and calcium homeostasis: Cellular and molecular mechanisms. *Biology of sex differences* **6**, 9-9 (2015). <u>https://doi.org:10.1186/s13293-015-0027-9</u>
- 43 Gharbi-Meliani, A. *et al.* The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study. (2021).
- 44 Park, J.-H. & Marwick, T. H. Use and Limitations of E/e' to Assess Left Ventricular Filling Pressure by Echocardiography. *Journal of cardiovascular ultrasound* **19**, 169 (2011). <u>https://doi.org:10.4250/jcu.2011.19.4.169</u>

 Table 1. General characteristics of study participants.

		NSHD	SABRE	UK Biobank
Variable		Count (%), <i>n</i> =1467	Count (%), <i>n</i> =1187	Cohort (%), <i>n</i> =32972
Exposure: APOE ε4 genotyp	e ε2ε2	8 (0.55%)	6 (0.51%)	178 (0.54%)
	ε2ε3	169 (11.54%)	130 (11.95%)	4046 (12.27%)
	$\epsilon 2\epsilon 4$	44 (3.00%)	27 (2.28%)	773 (2.34%)
	e3e3	855 (57.36%)	726 (61.16%)	19587 (59.41%)
	ε3ε4	343 (23.41%)	269 (22.66%)	7647 (23.19%)
	$\varepsilon 4 \varepsilon 4$	46 (3.14%)	29 (2.44%)	741 (2.25%)
Echo at 60-64 years	APOE <i>e4</i> status	Median (IQR)	Median (IQR)	Median (IQR)
EF	_/_	65.06 (60.02, 69.27)	62.17 (55.81, 68.51)	59.75 (55.84, 63.69)
	+/	64.73 (59.33, 69.43)	63.05 (57.66, 69.74)	59.64 (55.85, 63/66)
	+/-	- 66.68 (61.94, 69.34)	62.07 (56.71, 67.73)	60.10 (56.37, 63.95)
E/e'	_/_	7.72 (6.51, 9.20)	8.12 (7.11, 10.78)	N/A
	+/	7.52 (6.30, 8.87)	8.91 (7.51, 10.53)	N/A
	+/-	- 7.18 (6.07, 8.37)	8.35 (6.73, 9.86)	N/A
L <sub>PDSR</sub>	_/_	N/A	N/A	1.59 (1.23, 2.00)
	+/	N/A	N/A	1.61 (1.25, 2.01)
	+/-	- N/A	N/A	1.62 (1.27, 2.00)
R <sub>PDSR</sub>	_/_	N/A	N/A	-5.70 (-7.03, -4.38)
	+/	N/A	N/A	-5.77 (-7.05, -4.43)
	+/-	- N/A	N/A	-5.71 (-7.05, -4.43)
LVmass	_/_	108.89 (92.86, 131.80)	93.38 (79.59, 107.72)	82.71 (68.41, 100.79)
	+/	108.38 (87.62, 137.70)	93.75 (80.83, 109.64)	82.53 (68.51, 100.49)
	+/-	- 113.25 (98.08, 127.13)	91.24 (80.83, 109.2)	81.69 (68.78, 100.88)
MCF	_/_	0.47 (0.37, 0.59)	0.58 (0.49, 0.70)	1.07 (0.95, 1.21)
	+/	0.51 (0.39, 0.65)	0.60 (0.50, 0.71)	1.08 (0.95, 1.22)
	+/-	- 0.53 (0.42, 0.60)	0.62 (0.55, 0.68)	1.09 (0.97, 1.23)
LVPWTs	_/_	1.57 (1.40, 1.74)	1.48 (1.35, 1.62)	N/A
	+/	1.58 (1.42, 1.80)	1.45 (1.32, 1.59)	N/A
	+/-	- 1.60 (1.47, 1.74)	1.39 (1.26, 1.60)	N/A
LVPWT <sub>d</sub>	_/_	0.98 (0.87, 1.09)	1.02 (0.92, 1.13)	5.65 (5.14, 6.21)
	+/	0.98 (0.88, 1.10)	1.01 (0.91, 1.12)	5.64 (5.15, 6.23)
	+/-	0.96 (0.87, 1.04)	0.98 (0.90, 1.10)	5.67 (5.17, 6.26)
IVS <sub>s</sub>	_/_	1.50 (1.34, 1.68)	1.58 (1.42, 1.74)	N/A
	+/	1.51 (1.35, 1.69)	1.57 (1.40, 1.76)	N/A
	+/-	- 1.50 (1.36, 1.64)	1.51 (1.44, 1.70)	N/A

IVS <sub>d</sub>	_/_	1.04 (0.91, 1.18)	1.15 (1.03, 1.30)	5.59 (4.98, 6.13)
	+/	1.04 (0.90, 1.18)	1.14 (1.01, 1.29)	27.96 (24.92, 30.61)
				5.58 (4.98, 6.12)
	+/+	1.09 (0.93, 1.15)	1.09 (1.04, 1.21)	5.58 (4.97, 6.12)
Covariates		Count (%) or Median (IQR)	Count (%) or Median (IQR)	Count (%) or Median (IQR)
Age		62 (0)	52.08 (7.27)	63.63 (7.57%)
Sex, male		708 (48.32%)	911 (76.75%)	15750 (47.77%)
BMI		26.94 (24.49, 30.22)	27.00 (24.35, 29.90)	25.84 (23.46, 28.77)
CVD, Yes		875 (8.72%)	232 (19.55%)	2153 (6.53%)
Diabetes, Yes		321 (21.88%)	256 (21.57%)	1991 (6.04%)
High cholesterol, Yes		282 (19.22%)	235 (19.80%)	6145 (18.64%)
Hypertension		719 (50.65%)	700 (58.98%)	9106 (27.62%)

Participants were included in the study if they had the apolipoprotein APOE  $\varepsilon$  genotype and at least one echocardiographic parameter available.

-/-, no APOE ɛ4 carriage; +/-, heterozygous APOE ɛ4 carriage; +/+, homozygous APOE ɛ4 carriage; APOE, apolipoprotein E, BMI, body mass index; CVD, cardiovascular disease; Echo, echocardiography; EF, ejection fraction; IQR, interquartile, IVSs<sub>id</sub>, interventricular septal thickness in systole/diastole; LVmassi, left ventricular mass indexed to body surface area, LVPWT<sub>sid</sub> left ventricular posterior wall thickness in systole/diastole; MCF<sub>i</sub>, myocardial contraction fraction; N/A, not applicable; NSHD, National Survey of Health and Development; L/R<sub>PDSR</sub>, longitudinal/radial peak diastolic strain rate; SABRE, Southall and Brent Revisited.

s		Model 1 (unadjusted)			Model 2 (adjuste age, sex SEP)	2 ed for k, and	Model (adjust BMI)	3 <sup>+</sup> ed for	Model 4 (adjusted fo CVD)	or	Model : (adjuste diabete	5 ed for s)	Model 6 (adjuste high choleste	o ed for erol)	Model 7 (adjuste HT)	d for
Outcome	APOE <i>ɛ4</i> status	n	Exp β (95% CI)	<i>p</i> - value	Exp β (95% CI)	<i>p</i> - value	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> - value	Exp β (95% CI)	<i>p</i> - value	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> -value
EF	No <i>APOE ε4</i>	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
	APOE ε4 carriers		1.00 (0.98, 1.03)	0.670	1.00 (0.99, 1.02)	0.687	1.00 (0.98, 1.03)	0.677	1.00 (0.99, 1.02)	0.773	1.00 (0.98, 1.02)	0.981	1.01 (0.98, 1.03)	0.689	1.00 (0.98, 1.02)	0.697
E/e'	No <i>APOE ε4</i>	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
	APOE ε4 carriers		0.99 (0.96, 1.01)	0.263	0.99 (0.97, 1.02)	0.453	0.99 (0.96, 1.01)	0.274	0.98 (0.96, 1.01)	0.214	0.99 (0.95, 1.03)	0.529	0.98 (0.95, 1.01)	0.116	0.99 (0.96, 1.04)	0.302
LVmass	No <i>APOE ε4</i>	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
	APOE ε4 carriers		1.02 (0.98, 1.07)	0.347	1.01 (0.98, 1.04)	0.607	1.03 (0.98, 1.07)	0.258	1.03 (0.97, 1.09)	0.320	1.03 (0.98, 1.09)	0.249	1.02 (0.98, 1.06)	0.294	1.03 (0.98, 1.08)	0.308
MCF	No <i>APOE ε4</i>	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
	APOE ε4 carriers	2074	1.04 (1.01, 1.07)	0.016	1.04 (1.01, 1.07)	0.008	1.04 (1.01, 1.07)	0.007	1.03 (1.00, 1.06)	0.046	1.03 (1.00, 1.07)	0.069	1.05 (1.00, 1.09)	0.038	1.03 (1.00, 1.06)	0.030
LVPWTs	No <i>APOE ε4</i>	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref

Table 2. Associations between APOE  $\varepsilon 4$  genotypes and echocardiographic data in older age by comparing non-APOE  $\varepsilon 4$  ( $\varepsilon 2\varepsilon 2$ ,  $\varepsilon 2\varepsilon 3$ ,  $\varepsilon 2\varepsilon 3$ ) with APOE  $\varepsilon 4$  ( $\varepsilon 2\varepsilon 4$ ,  $\varepsilon 3\varepsilon 4$  and  $\varepsilon 4\varepsilon 4$ ) genotypes in the meta-analysis pooling SABRE and NSHD data.

	APOE ε4		1.00	0.859	0.99	0.621	1.00	0.847	1.00 (0.96,	0.907	1.00	0.891	1.00	0.971	1.00	0.882
	carriers		(0.97,		(0.97,		(0.97,		1.03)		(0.97,		(0.97,		(0.97,	
			1.03)		1.02)		1.03)				1.04)		1.03)		1.03)	
LVPWT <sub>d</sub>	No <i>APOE ε4</i>	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
	APOE ε4 carriers		1.00 (0.97, 1.04)	0.780	1.00 (0.98, 1.02)	0.967	1.01 (0.97, 1.04)	0.745	1.00 (0.97, 1.04)	0.805	1.01 (0.98, 1.04)	0.710	1.00 (0.98, 1.02)	0.807	1.01 (0.97, 1.04)	0.751
IVSs	No <i>APOE ε4</i>	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
	APOE ε4 carriers		1.00 (0.98, 1.01)	0.843	0.99 (0.98, 1.01)	0.480	0.99 (0.98, 1.01)	0.478	1.00 (0.99, 1.02)	0.262	1.00 (0.99, 1.02)	0.881	0.99 (0.98, 1.01)	0.518	1.00 (0.99, 1.02)	0.992
IVSd	No <i>APOE ε4</i>	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
	APOE ε4 carriers		1.00 (0.98, 1.02)	0.776	1.00 (0.98, 1.02)	0.972	1.00 (0.99, 1.02)	0.758	1.00 (0.99, 1.02)	0.644	1.01 (0.99, 1.03)	0.389	1.00 (0.98, 1.03)	0.759	1.00 (0.99, 1.02)	0.605

All reported analyses here consisted of random-effects meta-analyses of coefficients derived from generalized linear models with gamma distribution and log link from both NSHD and SABRE. Significant *p*-values are highlighted in bold.

β, beta regression coefficient; CI, confidence interval; exp, exponentiated; ref, reference. Other abbreviations as in Table 1.

S		Model 1 (unadjusted)			Model (adjust age, sey SEP)	2 ed for x, and	Model ( (adjuste BMI)	3 <sup>+</sup> ed for	Model 4 (adjusted fo CVD)	Model 4 (adjusted for CVD)		5 ed for s)	Model 6 (adjuste high choleste	ó ed for erol)	Model 7 (adjusted for HT)		
Outcome	APOE ε4 status	n	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> - value	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> - value	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> -value	
EF	No APOE ε4 APOE ε4 carriers	ref 32644	ref 1.00 (1.00, 1.00)	ref 0.916	ref 1.00 (1.00, 1.00)	ref 0.453	ref 1.00 (1.00, 1.00)	ref 0.902	ref 1.00 (1.00, 1.00)	ref 0.836	ref 1.00 (1.00, 1.00)	ref 0.830	ref 1.00 (1.00, 1.00)	ref 0.840	ref 1.00 (1.00, 1.00)	ref 0.914	
L <sub>PDSR</sub>	No APOE $\varepsilon 4$ APOE $\varepsilon 4$ carriers	ref 32505	ref 1.02 (1.00, 1.03)	ref 0.045	ref 1.00 (0.99, 1.02)	ref 0.657	ref 1.02 (1.00, 1.03)	ref 0.063	ref 1.02 (1.00, 1.03)	ref 0.032	ref 1.01 (1.00, 1.03)	ref 0.095	ref 1.02 (1.01, 1.04)	ref 0.002	ref 1.02 (1.00, 1.03)	ref 0.059	
R <sub>PDSR</sub>	No APOE ε4 APOE ε4 carriers	ref 32505	ref 0.95 (0.90, 1.00)	ref 0.05	ref 0.98 (0.94, 1.04)	ref 0.536	ref 0.96 (0.91, 1.01)	ref 0.102	ref 0.95 (0.90, 1.00)	ref 0.034	ref 0.96 (0.91, 1.01)	ref 0.106	ref 0.93 (0.88, 0.98)	ref 0.004	ref 0.95 (0.90, 1.00)	ref 0.063	
LVmass	No APOE ε4 APOE ε4 carriers	ref 32644	ref 1.00 (0.99, 1.01)	ref 0.568	ref 1.00 (1.00, 1.01)	ref 0.242	ref 1.00 (0.99, 1.01)	ref 0.798	ref 1.00 (0.99, 1.00)	ref 0.350	ref 1.00 (0.99, 1.01)	ref 0.815	ref 1.00 (0.99, 1.00)	ref 0.127	ref 1.00 (0.99, 1.01)	ref 0.695	
MCF	No APOE ε4 APOE ε4 carriers	ref 32643	ref 1.01 (1.00, 1.01)	ref 0.020	ref 1.01 (1.00, 1.01)	ref 0.080	ref 1.00 (1.00, 1.01)	ref 0.079	ref 1.01 (1.00, 1.01)	ref 0.006	ref 1.00 (1.00, 1.01)	ref 0.058	ref 1.01 (1.01, 1.01)	ref 0.000 1	ref 1.01 (1.00, 1.01)	ref 0.034	
PWT	No APOE $\varepsilon 4$ APOE $\varepsilon 4$ carriers	ref 32605	ref 1.00 (0.99, 1.00)	ref 0.094	ref 1.00 (1.00, 1.00) ref	ref 0.881	ref 1.00 (1.00, 1.00) ref	ref 0.448	ref 1.00 (0.99, 1.00)	ref 0.037	ref 1.00 (1.00, 1.00) ref	ref 0.257	ref 0.99 (0.99, 1.00)	ref 0.002	ref 1.00 (1.00, 1.00)	ref 0.132	

Table 3. Associations between *APOE*  $\varepsilon$ 4 genotypes and echocardiographic data in older age by comparing non-*APOE*  $\varepsilon$ 4 ( $\varepsilon$ 2 $\varepsilon$ 2,  $\varepsilon$ 2 $\varepsilon$ 3,  $\varepsilon$ 2 $\varepsilon$ 3) with *APOE*  $\varepsilon$ 4 ( $\varepsilon$ 2 $\varepsilon$ 4,  $\varepsilon$ 3 $\varepsilon$ 4 and  $\varepsilon$ 4 $\varepsilon$ 4) genotypes in UK Biobank.

ΑΡΟΕ ε4	32605	1.00	0.128	1.00	0.986	1.00	0.537	1.00 (0.99,	0.056	1.00	0.281	1.00	0.003	1.00	0.179
carriers		(0.99,		(1.00,		(1.00,		1.00)		(0.99,		(0.99,		(0.99,	
		1.00)		1.00)		1.00)				1.00)		1.00)		1.00)	

All reported analyses here consisted of generalized linear models with gamma distribution and log link, except for the longitudinal and radial PDSR analyses where generalized linear models with Gaussian distribution and identity link were used instead. Significant *p*-values are highlighted in bold. Abbreviations as in **Tables 1** and **2**.

			Model (unadj	1 usted)		Model 2 (adjuste age, sex SEP)	Model 2 (adjusted for age, sex and SEP)		Model 3 (adjusted for BMI)		Model 4 (adjusted for CVD)		5 ed for s)	Model 6 (adjusted for high cholesterol)		Model 7 (adjusted for HT)	
Outco me:	Cohort	Analysis	n	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> - value	Exp β (95% CI)	<i>p</i> - value	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> - value	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> -value
MCF	UK biobank	APOE ε4- linear	32644	1.01 (1.00, 1.02)	0.082	1.01 (1.00, 1.02)	0.152	1.01 (1.00, 1.02)	0.239	1.01 (1.00, 1.02)	0.036	1.01 (1.00, 1.02)	0.123	1.01 (1.00, 1.02)	0.006	1.01 (1.00, 1.02)	0.109
	SABRE+ NSHD meta- analysis	APOE ε4- linear	2074	1.02 (0.96, 1.08)	0.544	1.02 (0.96, 1.08)	0.516	1.03 (0.97, 1.09)	0.906	1.01 (0.95, 1.07)	0.729	1.00 (0.95, 1.07)	0.870	1.01 (0.94, 1.08)	0.780	1.01 (0.96, 1.07)	0.670
	UK biobank	APOE ε4 - quadratic	32644	1.00 (0.99, 1.01)	0.770	1.00 (1.00, 1.01)	0.424	1.00 (0.99, 1.01)	0.972	1.00 (1.00, 1.01)	0.687	1.00 (1.00, 1.01)	0.711	1.00 (1.00, 1.01)	0.723	1.00 (0.99, 1.01)	0.803
	SABRE+ NSHD meta- analysis	APOE ε4 - quadratic	2074	0.98 (0.93, 1.03)	0.475	0.98 (0.93, 1.03)	0.451	0.99 (0.94, 1.04)	0.675	0.98 (0.94, 1.02)	0.327	0.98 (0.94, 1.02)	0.251	0.97 (0.92, 1.01)	0.174	0.98 (0.94, 1.02)	0.312
Longitu dinal PDSR	UK biobank	APOE ε4- linear	32505	1.01 (0.98, 1.04)	0.557	1.00 (0.97, 1.03)	0.855	1.01 (0.97, 1.04)	0.756	1.01 (0.98, 1.04)	0.476	1.01 (0.98, 1.04)	0.678	1.02 (0.99, 1.05)	0.199	1.01 (0.97, 1.04)	0.630
	UK biobank	APOE ε4 - quadratic		0.99 (0.97, 1.01)	0.499	1.00 (0.98, 1.02)	0.640	0.99 (0.97, 1.01)	0.388	0.99 (0.97, 1.02)	0.524	0.99 (0.97, 1.02)	0.524	0.99 (0.97, 1.02)	0.526	0.99 (0.97, 1.01)	0.477
Radial PDSR	UK biobank	APOE ε4- linear	32505	0.98 (0.88, 1.09)	0.725	1.02 (0.92, 1.13)	0.786	0.99 (0.89, 1.10)	0.282	0.97 (0.87, 1.08)	0.614	0.99 (0.89, 1.10)	0.858	0.95 (0.85, 1.06)	0.321	0.99 (0.88, 1.10)	0.789
	UK biobank	APOE ε4 - quadratic		1.03 (0.96, 1.11)	0.379	1.02 (0.96, 1.10)	0.503	1.03 (0.96, 1.11)	0.416	1.03 (0.96, 1.11)	0.405	1.03 (0.96, 1.11)	0.400	1.03 (0.96, 1.11)	0.399	1.04 (0.96, 1.11)	0.365

Table 4. Dose response of *APOE ɛ*4 carriage when assessing the association between *APOE ɛ*4 genotype and echocardiographic and CMR data in older age.

The APOE  $\varepsilon 4$  genotypes were coded as an ordered category based on the number of  $\varepsilon 4$  possessed. Thus, level 0 encompassed  $\varepsilon 2\varepsilon 2$ ,  $\varepsilon 2\varepsilon 3$ ,  $\varepsilon 2\varepsilon 3$ ,  $\varepsilon 2\varepsilon 3$ , level 1  $\varepsilon 2\varepsilon 4$  and  $\varepsilon 3$   $\varepsilon 4$  and level 2  $\varepsilon 4\varepsilon 4$ . Given the existence of two levels, generalized linear models and orthogonal polynomial contrasts with 2 equally spaced levels (i.e., linear and quadratic) were employed to look for a dose response by  $\varepsilon 4$  variants. Significant *p*-values are highlighted in bold. Abbreviations as in **Table 2**.

			Model (unadju	1 usted)		Model 2 (adjuste sex and	Model 2 (adjusted for sex and SEP)		Model 3 (adjusted for BMI)		4 ed for	Model 5 (adjusted for diabetes)		Model (adjust high cholest	6 ed for erol)	Model 7 (adjusted for HT)	
Outco me:	Cohort	Analysis	n	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> - value	Exp β (95% CI)	<i>p</i> -value	Exp β (95% CI)	<i>p</i> -value
MCF	UK Biobank	Heterozygo us-APOE ɛ4	31909	1.01 (1.00, 1.01)	0.047	1.00 (0.99, 1.01)	0.140	1.00 (1.00, 1.01)	0.120	1.01 (1.00, 1.01)	0.019	1.00 (1.00, 1.01)	0.116	1.01 (1.00, 1.01)	0.000 8	1.00 (1.00, 1.01)	0.069
	SABRE+ NSHD meta- analysis	Heterozygo us-APOE ε4	2019	1.04 (1.01, 1.07)	0.016	1.04 (1.01, 1.07)	0.013	1.04 (1.01, 1.07)	0.018	1.03 (1.00, 1.06)	0.043	1.03 (1.00, 1.07)	0.060	1.05 (1.00, 1.10)	0.040	1.03 (1.00, 1.06)	0.028
	UK Biobank	Homozygo us-APOE ε4	25086	1.01 (1.00, 1.03)	0.083	1.01 (1.00, 1.02)	0.166	1.01 (1.00, 1.02)	0.252	1.01 (1.00, 1.03)	0.034	1.01 (1.00, 1.02)	0.115	1.02 (1.01, 1.03)	0.006	1.01 (1.00, 1.02)	0.123
	SABRE+ NSHD meta- analysis	Homozygo us-APOE ε4	1539	1.03 (0.95, 1.11)	0.544	1.03 (0.95, 1.11)	0.517	1.04 (0.96, 1.13)	0.350	1.02 (0.92, 1.10)	0.704	1.01 (0.93, 1.09)	0.874	1.01 (0.92, 1.11)	0.812	1.02 (0.94, 1.10)	0.652
Longitu dinal PDSR	UK biobank	Heterozygo us-APOE ε4	31909	1.02 (1.00, 1.03)	0.049	1.00 (0.99, 1.02)	0.610	1.02 (1.00, 1.03)	0.059	1.02 (1.00, 1.03)	0.038	1.01 (1.00, 1.03)	0.099	1.02 (1.01, 1.04)	0.004	1.02 (1.00, 1.03)	0.062
	UK biobank	Heterozygo us-APOE ε4	24965	1.01 (0.97, 1.06)	0.556	1.00 (0.96, 1.04)	0.843	1.01 (0.96, 1.05)	0.754	1.02 (0.97, 1.06)	0.469	1.01 (0.97, 1.06)	0.679	1.03 (0.98, 1.08)	0.206	1.01 (0.97, 1.06)	0.631
Radial PDSR	UK biobank	Heterozygo us-APOE ε4	31773	0.95 (0.90, 1.00)	0.049	0.98 (0.93, 1.03)	0.467	0.96 (0.90, 1.01)	0.094	0.94 (0.89, 1.00)	0.035	0.96 (0.91, 1.01)	0.097	0.93 (0.88, 0.98)	0.005	0.95 (0.90, 1.00)	0.058
	UK biobank	Heterozygo us-APOE ε4	24965	0.97 (0.83, 1.14)	0.726	1.02 (0.88, 1.18)	0.772	0.98 (0.84, 1.15)	0.820	0.96 (0.82, 1.12)	0.605	0.99 (0.85, 1.15)	0.859	0.93 (0.80, 1.08)	0.327	0.98 (0.84, 1.14)	0.789

Table 5. Associations between APOE  $\varepsilon 4$  genotypes and echocardiographic data in older age by comparing non-APOE  $\varepsilon 4$  ( $\varepsilon 2\varepsilon 2$ ,  $\varepsilon 2\varepsilon 3$ ,  $\varepsilon 2\varepsilon 3$ ) with heterozygous-APOE  $\varepsilon 4$  ( $\varepsilon 2\varepsilon 4$  and  $\varepsilon 3\varepsilon 4$ ) and homozygous-APOE  $\varepsilon 4$  ( $\varepsilon 4\varepsilon 4$ ) genotypes.

All reported analyses here consisted of generalized linear models with gamma distribution and log link. Significant *p*-values are highlighted in bold. Abbreviations as in Table 2.

## Figure 1. Associations between APOE *ɛ*4 genotypes and echocardiographic and cardiac MRI data in older age.

As *APOE*  $\varepsilon$ 4 carriers had a higher myocardial contraction fraction, the mechanistic pathways were explored by adjusting the models for mediators (body mass index, cardiovascular disease, diabetes, high cholesterol, and hypertension).

EF, ejection fraction; IVS, interventricular septal thickness; LVmass, left ventricular mass, LVPW left ventricular posterior wall thickness; MCF myocardial contraction fraction; PDSR, longitudinal/radial peak diastolic strain rate.



## Figure 2. Graphical abstract.

Combining data from three British cohorts–1946 National Survey of Health and Development (NSHD), Southall and Brent Revised (SABRE) and UK Biobank–we explored whether *APOE*  $\varepsilon$ 4 carriage associates with beneficial or unfavorable left ventricular (LV) structural and functional parameters by echocardiography and cardiovascular magnetic resonance (CMR) in older age. Based on the presence of *APOE*  $\varepsilon$ 4, genotypes were divided into: *APOE*  $\varepsilon$ 4 ( $\varepsilon$ 2 $\varepsilon$ 4,  $\varepsilon$ 3 $\varepsilon$ 4,  $\varepsilon$ 4 $\varepsilon$ 4) and non-*APOE*  $\varepsilon$ 4 carriers. Compared to the non-*APOE*  $\varepsilon$ 4 group, *APOE*  $\varepsilon$ 4 carriers had a higher myocardial contraction fraction resulting in greater LV stroke volume generation per 1 mL of myocardium and better longitudinal strain rates compared to non *APOE*  $\varepsilon$ 4 carriers.

